Breaking News
September 25, 2018 - Antibiotics best paediatric treatment for children’s chronic wet cough
September 25, 2018 - Looking beyond opioids: Stanford pain psychologist briefs Congress
September 25, 2018 - Organs actively fighting back against autoimmune diseases, finds study
September 25, 2018 - Lancaster professor aims to understand how genes affect smoking cessation
September 25, 2018 - Human-oriented perspective needed to better understand Parkinson’s disease
September 25, 2018 - Physical activity may have beneficial effects for people with rare Alzheimer’s disease
September 25, 2018 - FDA Updates on Valsartan Recalls
September 25, 2018 - 3-D-printed tracheal splints used in groundbreaking pediatric surgery
September 25, 2018 - Who is the designated driver, or proxy, for your health decisions?
September 25, 2018 - New chemo-optogenetic method enables multi-directional activity control of cellular processes
September 25, 2018 - Study explores link between genetic predisposition to Alzheimer’s and cardiometabolic risk factors
September 25, 2018 - NeoTract presents new clinical data from studies of UroLift System for patients with BPH
September 25, 2018 - Statins Improve Long-Term Survival After AAA Repair
September 25, 2018 - Novel brain network linked to chronic pain in Parkinson’s disease
September 25, 2018 - Researchers reassess negative pressure wound therapy as its benefit and harm remain unclear
September 25, 2018 - Older adults with ‘fall plan of care’ less likely to suffer fall-related hospitalizations
September 25, 2018 - FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials
September 25, 2018 - IME Medical Electrospinning establishes state-of-the-art manufacturing lab facilities
September 25, 2018 - Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results
September 25, 2018 - How to Protect Your Eyesight
September 25, 2018 - Novel approach allows researchers to define how cells in the retina respond to diabetes
September 25, 2018 - Columbia University announces winners of 2018 Louisa Gross Horwitz Prize
September 25, 2018 - Clinical trial investigators found non-compliant with requirement to report results on EU register
September 25, 2018 - Study analyzes quality of protein supplements in function of source, treatment and storage
September 25, 2018 - FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome
September 25, 2018 - U.S. Alzheimer’s Cases to Nearly Triple by 2060
September 25, 2018 - Improving cell replacement therapy for Parkinson’s disease
September 25, 2018 - Genervon reports new findings that drug candidate GM6 attenuates Alzheimer’s disease in mice model
September 25, 2018 - FDA approves new 5 mm diameter drug-eluting stent from Cook Medical
September 25, 2018 - New $17.8 million grant ensures USC at forefront of research on tobacco-related health risks
September 25, 2018 - Researchers analyze response to combination immunotherapy for patients with rare skin cancer
September 25, 2018 - Study sheds light on how brain protein may be involved neurodevelopmental disorders
September 25, 2018 - Where to draw the line on incentives
September 25, 2018 - Solid fuel use linked with increased risk of hospitalization or death from respiratory diseases
September 25, 2018 - ‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms
September 25, 2018 - Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE
September 25, 2018 - Global leaders must make bold commitments at first-ever UN tuberculosis summit
September 25, 2018 - Brief sleep intervention works long-term to prevent child obesity
September 25, 2018 - Vaping among kids and teens a growing concern
September 25, 2018 - Public launch of products and application solutions from Porvair Laboratory Division
September 25, 2018 - Harmful H. pylori may play a role in Parkinson’s disease
September 25, 2018 - Researchers develop way to measure different types of fear of falling in patients with Parkinson’s
September 25, 2018 - Fracture causes bone density losses throughout the body
September 25, 2018 - Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder
September 25, 2018 - Hybrid theranostic complex shows high therapeutic efficacy against tumor cells
September 25, 2018 - FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 25, 2018 - Toxicological evaluation and dosimetry estimation of potential PET radiotracer
September 25, 2018 - 5 obstacles parents commonly face in child obesity treatment and how to overcome them
September 25, 2018 - Immunologist to study how Chikungunya causes devastating effects in older adults
September 25, 2018 - Rural borderland communities vulnerable to high stress impacting mental and physical health
September 25, 2018 - SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship
September 25, 2018 - Common painkiller not effective in controlling chronic pain after traumatic nerve injury
September 25, 2018 - New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer
September 25, 2018 - Environmentally-induced gene activity influences IQ test performance
September 25, 2018 - Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI
September 25, 2018 - FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
September 25, 2018 - Medical device company settles US case over false claims
September 25, 2018 - Trying to get answers: One woman’s quest for a diagnosis
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Triple Therapy Improves PFS in Certain Breast Ca Patients

Triple Therapy Improves PFS in Certain Breast Ca Patients

image_pdfDownload PDFimage_print

Action Points

  • Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib (Tykerb) and trastuzumab (Herceptin) + an aromatase inhibitor (AI) improved progression-free survival (PFS) versus single HER2 blockade in HER2-positive/hormone receptor (HR)-positive metastatic breast cancer.
  • Note that HER2–positive breast cancer (BC) constitutes approximately 20% to 25% of BC and is associated with poor prognosis,and approximately 50% of HER2-positive BCs are HR-positive, so HER2-positive/HR-positive represent roughly 10% of all BCs.

Targeting HER2 with two agents — lapatinib (Tykerb) and trastuzumab (Herceptin) — and adding an aromatase inhibitor (AI) significantly improved progression-free survival (PFS) compared to trastuzumab/AI in patients with HER2-positive and hormone receptor-positive metastatic breast cancer, researchers found.

Results from the large, randomized, phase III ALTERNATIVE trial demonstrated that the combination of lapatinib/trastuzumab/AI provided a clinically meaningful prolongation of PFS compared with trastuzumab/AI with a median PFS of 11.0 versus 5.7 months, respectively, according to Stephen R.D. Johnston, MA, PhD, of The Royal Marsden NHS Foundation Trust in London, and colleagues.

This represented a statistically significant 38% reduction in the risk of disease progression (hazard ratio [HR] 0.62; P=0.0064) in patients not suitable for chemotherapy, the study authors reported online in the Journal of Clinical Oncology. Lapatinib/trastuzumab/AI was also relatively well tolerated compared with trastuzumab/AI.

These findings indicate that patients with HER2-positive/HR-positive MBC who are not candidates for chemotherapy can be adequately treated with dual HER2 blockade plus an AI, Johnston and colleagues emphasized. “Although survival data were immature, there was also a trend in favor of the dual-blockade treatment (median 46.0 versus 40.0 months),” they wrote.

The PFS benefit of lapatinib/trastuzumab/AI compared with trastuzumab/AI was consistent across patient subgroups. The overall response rate (ORR) and clinical benefit rate (CBR) also favored the lapatinib/trastuzumab/AI combination over trastuzumab/AI (ORR 31.7% versus 13.7%, and CBR 41% versus 31%, respectively).

“Dual HER2 blockade enhances clinical benefit versus single HER2 blockade,” the study authors noted. “The use of dual anti-HER2 blockade represents a potential strategy to further improve the outcome of these patients,” Johnston and colleagues added.

The ALTERNATIVE trial enrolled 355 postmenopausal women from 112 sites in 29 countries. All patients had received prior endocrine therapy and experienced disease progression after prior neo(adjuvant)/first-line trastuzumab plus chemotherapy. Patients were randomly assigned 1:1:1 to lapatinib/trastuzumab/AI, trastuzumab/AI, or lapatinib/AI.

In the lapatinib/trastuzumab/AI arm, patients took 1,000 mg/day oral lapatinib. In the lapatinib/AI arm, patients took 1,500 mg/day. In both trastuzumab arms, patients received an IV loading dose of 8 mg/kg trastuzumab followed by a maintenance dose of 6 mg/kg every 3 weeks. Oral AIs included letrozole (Femara; 2.5 mg/day), antinuclear antibodies (1 mg/day), or exemestane (Aromasin; 25 mg/day).

The median PFS with lapatinib/AI versus trastuzumab/AI was 8.3 versus 5.7 months (HR 0.71; P=0.0361).

Common adverse events were seen in lapatinib/trastuzumab/AI; trastuzumab/AI; and lapatinib/AI, respectively, and included:

  • Diarrhea (69%, 9%, and 51%)
  • Rash (36%, 2%, and 28%)
  • Nausea (22%, 9%, and 22%)
  • Paronychia (30%, 0%, and 15%)

Frequency of adverse events, mostly grade 1 or 2, was 92% in the two lapatinib arms and 74% in the trastuzumab arm. Serious AEs were reported across the three study groups, with discontinuation lowest in the lapatinib/trastuzumab/AI arm (3%) compared to the trastuzumab/AI (6%) and lapatinib/AI (9%) arms.

Other studies looking at HER2 blockade have been conducted in different patient populations, so “cross-trial comparisons need to be interpreted with caution,” the study authors warned. Although the PFS outcome in ALTERNATIVE lines up with results from other studies, there are a limited number of trials designed for patients with HER2-positive/HR-positive metastatic breast cancer, they pointed out.

In the phase II PERTAIN study of locally advanced or metastatic hormone receptor-positive HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab and an AI in the first-line setting significantly improved PFS by 3 months. The median PFS was 18.9 months with pertuzumab, trastuzumab and endocrine therapy compared to 15.80 months with trastuzumab plus endocrine therapy.

However, only 77% of patients were trastuzumab-naive and 55% of patients had received induction chemotherapy in this first-line setting, the ALTERNATIVE study authors noted.

The rationale for PERTAIN came from the TAnDEM study, which showed that adding trastuzumab to anastrozole (Arimidex) significantly improved PFS over anastrozole alone. The CLEOPATRA study also demonstrated improved PFS and OS with the addition of pertuzumab to trastuzumab plus docetaxel.

These findings contrast the lack of benefit observed with lapatinib in the adjuvant setting in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial, Johnston and colleagues pointed out. In addition, the APHINITY trial demonstrated only a modest benefit with pertuzumab.

“This discrepancy may be the result, at least in part, of the excellent outcome with adjuvant single HER2 blockade with TRAS, making the demonstration of additional benefit with dual blockade harder. Dual HER2 blockade may benefit only a small subset of high-risk patients,” they suggested.

Similarly, results from an earlier international trial showed that adjuvant therapy with two HER2-targeted drugs failed to improve disease-free survival in early breast cancer compared with trastuzumab monotherapy. Concurrent administration of lapatinib and trastuzumab resulted in a nonsignificant 16% reduction in DFS compared with trastuzumab alone.

However, in a nonrandomized phase II study, the combination of lapatinib and trastuzumab was effective and well-tolerated in patients with HER2+ breast cancer who had received up to two lines of therapy for advanced disease. The study also showed that metabolic imaging appeared to be helpful for selecting poor responders in advance, thus sparing them the toxicity of chemotherapy.

Original funding for the ALTERNATIVE study was provided by GlaxoSmithKline. As of March 2, 2015, lapatinib was acquired by Novartis, the current sponsor of this study. Johnston reported relationships with Novartis, Eli Lilly, AstraZeneca, OBI Pharma, Puma Biotechnology, and Pfizer. A number of study co-authors also reported relationships with industry, including GlaxoSmithKline and Novartis.

2017-12-28T14:30:00-0500

Tagged with:

About author

Related Articles